MCID: DFF036
MIFTS: 50

Differentiated Thyroid Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Differentiated Thyroid Carcinoma

MalaCards integrated aliases for Differentiated Thyroid Carcinoma:

Name: Differentiated Thyroid Carcinoma 58 28 16
Papillary or Follicular Thyroid Carcinoma 58
Differentiated Thyroid Gland Carcinoma 71
Well-Differentiated Thyroid Carcinoma 58

Characteristics:


Prevelance:

1-9/100000 (Worldwide, Europe) 58

Age Of Onset:

Adolescent,Adult,Childhood 58

Classifications:

Orphanet: 58  
Rare endocrine diseases


External Ids:

ICD10 via Orphanet 32 C73
UMLS via Orphanet 72 C0238463
Orphanet 58 ORPHA146
UMLS 71 C1337013

Summaries for Differentiated Thyroid Carcinoma

Orphanet: 58 A rare, slow-growing, epithelial thyroid carcinoma typically presenting as an asymptomatic thyroid mass and is classed as either papillary thyroid cancer (PTC), follicular thyroid cancer (FTC) or Hurthle cell thyroid cancer (HCTC).

MalaCards based summary: Differentiated Thyroid Carcinoma, also known as papillary or follicular thyroid carcinoma, is related to thyroid cancer, nonmedullary, 2 and goiter. An important gene associated with Differentiated Thyroid Carcinoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are Signal Transduction and RAF/MAP kinase cascade. The drugs Selenium and Trace Elements have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and salivary gland, and related phenotypes are Decreased viability and Reduced mammosphere formation

Related Diseases for Differentiated Thyroid Carcinoma

Diseases related to Differentiated Thyroid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 395)
# Related Disease Score Top Affiliating Genes
1 thyroid cancer, nonmedullary, 2 31.5 PPARG PAX8 NRAS HRAS BRAF
2 goiter 31.5 RET PAX8 HRAS
3 papillary carcinoma 31.1 RET PPARG PAX8 NTRK1 NCOA4 CCDC6
4 nodular goiter 31.1 RET HRAS BRAF
5 thyroid tumor 31.0 RET NRAS KRAS HRAS BRAF
6 adenoma 30.9 RET KRAS HRAS BRAF
7 hashimoto thyroiditis 30.9 RET NRAS NCOA4 KRAS HRAS BRAF
8 multinodular goiter 30.8 RET PAX8 NCOA4 EIF1AX
9 thyroid carcinoma, familial medullary 30.8 RET NTRK1 KRAS BRAF
10 exanthem 30.7 KRAS HRAS ALK
11 thyroid gland follicular carcinoma 30.7 RET PPARG PAX8 NTRK3 NTRK1 NRAS
12 blastoma 30.5 RET KRAS HRAS
13 thyroid gland medullary carcinoma 30.4 RET PAX8 NTRK1 NCOA4 CCDC6
14 histiocytosis 30.4 NRAS BRAF ALK
15 nephroma 30.4 NTRK3 ETV6 ALK
16 breast secretory carcinoma 30.3 NTRK3 ETV6
17 papillary adenocarcinoma 30.3 PAX8 KRAS HRAS
18 follicular adenoma 30.3 RET PPARG PAX8 NTRK1 HRAS BRAF
19 thyroid gland anaplastic carcinoma 30.1 RET PPARG PAX8 NTRK1 NRAS NCOA4
20 salivary gland carcinoma 30.1 PPARG NTRK3 NTRK1 ETV6
21 lung cancer susceptibility 3 30.0 NRAS KRAS HRAS BRAF ALK
22 struma ovarii 30.0 RET NRAS NCOA4 KRAS BRAF
23 neuroblastoma 29.9 RET PPARG NTRK3 NTRK1 NRAS HRAS
24 adenocarcinoma 29.9 RET NTRK1 KRAS HRAS BRAF ALK
25 leukemia, chronic lymphocytic 29.8 NRAS KRAS HRAS BRAF ALK
26 renal cell carcinoma, papillary, 1 29.7 RET PAX8 NRAS KRAS HRAS BRAF
27 leukemia, chronic myeloid 29.6 NTRK3 NTRK1 NRAS KRAS HRAS ETV6
28 thyroid gland cancer 29.6 RET PPARG PAX8 NTRK3 NTRK1 NRAS
29 thyroid carcinoma 11.6
30 thyroid carcinoma, nonmedullary, with or without cell oxyphilia 11.4
31 thyroid cancer, nonmedullary, 1 11.0
32 hypothyroidism, congenital, nongoitrous, 1 11.0
33 hypothyroidism, congenital, nongoitrous, 2 10.9
34 hypothyroidism, congenital, nongoitrous, 3 10.9
35 hypothyroidism 10.9
36 graves disease 1 10.8
37 hyperthyroidism 10.8
38 hypoparathyroidism 10.7
39 thyroiditis 10.7
40 factor vii deficiency 10.7
41 graves' disease 10.5
42 tatton-brown-rahman syndrome 10.4
43 meningeal melanoma 10.4 NRAS EIF1AX
44 spitz nevus 10.4 HRAS BRAF
45 48,xyyy 10.4
46 urethra transitional cell carcinoma 10.4 BRAF ALK
47 melphalan allergy 10.4 NRAS BRAF
48 trachea carcinoma in situ 10.4 KRAS HRAS
49 common bile duct neoplasm 10.4 KRAS HRAS
50 childhood leptomeningeal melanoma 10.4 NRAS HRAS

Graphical network of the top 20 diseases related to Differentiated Thyroid Carcinoma:



Diseases related to Differentiated Thyroid Carcinoma

Symptoms & Phenotypes for Differentiated Thyroid Carcinoma

GenomeRNAi Phenotypes related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

25 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.9 HRAS KRAS BRAF
2 Decreased viability GR00055-A-2 10.9 HRAS KRAS BRAF
3 Decreased viability GR00055-A-3 10.9 KRAS
4 Decreased viability GR00106-A-0 10.9 KRAS
5 Decreased viability GR00221-A-1 10.9 HRAS NRAS PPARG KRAS RET ALK
6 Decreased viability GR00221-A-2 10.9 HRAS PPARG KRAS NTRK3 RET
7 Decreased viability GR00221-A-3 10.9 HRAS NRAS NTRK1 PPARG
8 Decreased viability GR00221-A-4 10.9 PPARG NTRK3 RET BRAF ALK
9 Decreased viability GR00249-S 10.9 NTRK1 BRAF ALK
10 Decreased viability GR00301-A 10.9 NTRK1 KRAS RET BRAF
11 Decreased viability GR00381-A-1 10.9 KRAS BRAF
12 Decreased viability GR00386-A-1 10.9 PPARG
13 Decreased viability GR00402-S-2 10.9 RET
14 Reduced mammosphere formation GR00396-S 9.28 BRAF CCDC6 EIF1AX ETV6 HRAS KRAS
15 Increased transferrin (TF) endocytosis (mild increase), increased transferrin (TF) endosome elongation GR00363-A 8.65 HRAS

MGI Mouse Phenotypes related to Differentiated Thyroid Carcinoma:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 ALK BRAF CCDC6 ERC1 ETV6 HRAS
2 growth/size/body region MP:0005378 10.35 ALK BRAF ETV6 GOLGA5 HRAS KRAS
3 normal MP:0002873 10.33 ALK BRAF ERC1 ETV6 HRAS KRAS
4 no phenotypic analysis MP:0003012 10.24 ERC1 ETV6 HRAS KRAS NRAS NTRK1
5 endocrine/exocrine gland MP:0005379 10.2 ALK BRAF CCDC6 ETV6 HRAS KRAS
6 neoplasm MP:0002006 10.16 ALK BRAF ETV6 HRAS KRAS NRAS
7 renal/urinary system MP:0005367 10.13 BRAF ETV6 HRAS KRAS LPAR4 PAX8
8 embryo MP:0005380 10.13 BRAF ETV6 GOLGA5 KRAS LPAR4 NDUFA13
9 behavior/neurological MP:0005386 10.13 ALK BRAF GOLGA5 HRAS KRAS LPAR4
10 cardiovascular system MP:0005385 10.11 BRAF ETV6 HRAS KRAS LPAR4 NRAS
11 pigmentation MP:0001186 10.04 ALK BRAF KRAS NRAS NTRK1 PCM1
12 craniofacial MP:0005382 10.01 BRAF GOLGA5 HRAS KRAS LPAR4 NRAS
13 hearing/vestibular/ear MP:0005377 9.97 BRAF KRAS NTRK1 NTRK3 PAX8 PPARG
14 reproductive system MP:0005389 9.96 ALK BRAF GOLGA5 KRAS NDUFA13 NTRK3
15 skeleton MP:0005390 9.9 ALK BRAF ETV6 GOLGA5 HRAS KRAS
16 mortality/aging MP:0010768 9.89 ALK BRAF CCDC6 ERC1 ETV6 GOLGA5
17 integument MP:0010771 9.32 ALK BRAF ETV6 HRAS KRAS LPAR4

Drugs & Therapeutics for Differentiated Thyroid Carcinoma

Drugs for Differentiated Thyroid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selenium Approved, Investigational, Vet_approved Phase 4 7783-07-5, 7782-49-2 533
2 Trace Elements Phase 4
3 Antioxidants Phase 4
4 Micronutrients Phase 4
5 Selenium Supplement Phase 4
6 Protective Agents Phase 4
7
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
8
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
9
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
10
Lithium carbonate Approved Phase 2 554-13-2
11
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
12
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
13
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
14
Vemurafenib Approved Phase 2 918504-65-1 42611257
15
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
16
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760
17
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
18
Aldesleukin Approved Phase 2 110942-02-4
19
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
20
Nivolumab Approved Phase 2 946414-94-4
21
Ipilimumab Approved Phase 2 477202-00-9
22
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
23
Trametinib Approved Phase 2 871700-17-3 11707110
24
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
25
Iodine Approved, Investigational Phase 2 7553-56-2 807
26
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
27
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
28
Salmon calcitonin Approved, Investigational Phase 2 47931-85-1 155817456
29
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
30
Rivoceranib Investigational Phase 2 811803-05-1 11315474
31
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
32
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-16-7, 110-17-8 444266 444972
33
Spartalizumab Investigational Phase 2 1935694-88-4
34
Cadexomer iodine Experimental Phase 2 94820-09-4
35
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2 91976570
36 Liposomal doxorubicin Phase 2
37 Cyclooxygenase Inhibitors Phase 2
38 Cyclooxygenase 2 Inhibitors Phase 2
39 Anti-Inflammatory Agents, Non-Steroidal Phase 2
40 Anti-Inflammatory Agents Phase 2
41 Fluorodeoxyglucose F18 Phase 2
42 Psychotropic Drugs Phase 2
43 Antidepressive Agents Phase 2
44 Antirheumatic Agents Phase 2
45 Analgesics, Non-Narcotic Phase 2
46 Analgesics Phase 2
47 Immunoglobulins, Intravenous Phase 2
48 Albumin-Bound Paclitaxel Phase 2
49 Immunoglobulin G Phase 2
50 Antimitotic Agents Phase 2

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Distribution of Selenium in Patients With Differentiated Thyroid Carcinoma and Effect of Selenium Supplement on Prognosis of Patients With Differentiated Thyroid Carcinoma. Not yet recruiting NCT04683575 Phase 4 Selenium Yeast;Placebo
2 Phase 3 Trial of Adjuvant External Beam Radiotherapy for Locally Invasive Differentiated Thyroid Carcinoma Completed NCT00144079 Phase 3
3 A Prospective, Multicenter, Open Label Phase Ⅱ Clinical Trial of Doxorubicin Hydrochloride Liposome Injection Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma Unknown status NCT03387943 Phase 2 PLD;Cisplatin
4 The Effectiveness and Safety of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma: a Phase 2 Trial. Unknown status NCT03167385 Phase 2 Apatinib Mesylate
5 A Multi-center , Opened, Phase II Study of Safety and Efficacy of Sulfatinib in Advanced Medullary Thyroid Carcinoma ( MTC) and Iodine-refractory Differentiated Thyroid Carcinoma (DTC) Completed NCT02614495 Phase 2 Surufatinib
6 Phase II Study Of Celecoxib In Metastatic Differentiated Thyroid Carcinoma Completed NCT00061906 Phase 2 celecoxib
7 Preliminary Study of the Interest of Diffusion-weighted Magnetic Resonance Imaging in the Early Detection of Differentiated Thyroid Carcinoma Cervical Recurrence. Comparison with18F-FDG PET/CT Completed NCT02515084 Phase 2
8 A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma Completed NCT00118248 Phase 2 tanespimycin
9 A Phase II Study of External Beam Radiotherapy for Locoregionally Advanced or Recurrent Differentiated Thyroid Carcinoma Completed NCT01173289 Phase 2
10 The Effects of Lithium Carbonate on Low Dose Radioiodine Ablation in Early Thyroid Cancer Treatment Completed NCT00251316 Phase 2 Lithium Carbonate;Placebo
11 A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer Completed NCT00625846 Phase 2 Pazopanib Hydrochloride
12 Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy Completed NCT01811212 Phase 2 Cabozantinib S-malate
13 Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer Completed NCT01208051 Phase 1, Phase 2 Cediranib;Cediranib Maleate;Lenalidomide
14 Encorafenib/Binimetinib With or Without Nivolumab for Patients With Metastatic BRAF V600 Mutant Thyroid Cancer Recruiting NCT04061980 Phase 2 Binimetinib;Encorafenib
15 Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer Recruiting NCT04171622 Phase 2 Lenvatinib
16 Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers Recruiting NCT04759911 Phase 2 Selpercatinib
17 Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas Recruiting NCT03181100 Phase 2 Atezolizumab;Cobimetinib;Nab-paclitaxel;Paclitaxel;Vemurafenib
18 Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer Recruiting NCT04544111 Phase 2 Trametinib;Dabrafenib;PDR001
19 Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine
20 A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting Active, not recruiting NCT02041260 Phase 2 Cabozantinib
21 A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Vandetanib (ZD6474) in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy Active, not recruiting NCT00537095 Phase 2 Vandetanib
22 Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study Active, not recruiting NCT02973997 Phase 2 Lenvatinib;Lenvatinib Mesylate
23 Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy Active, not recruiting NCT03914300 Phase 2 Cabozantinib S-malate
24 Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
25 Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers Active, not recruiting NCT02393690 Phase 2 Selumetinib
26 A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers Active, not recruiting NCT02152995 Phase 2 Trametinib
27 Pembrolizumab in Combination With Standard 1st Line Therapy (Lenvatinib / Chemotherapy) for Locally Advanced or Metastatic Poorly Differentiated or Anaplastic Thyroid Cancer Suspended NCT04731740 Phase 2 Lenvatinib;Chemotherapy
28 Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer Terminated NCT03630120 Phase 2 Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
29 A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer Terminated NCT03506048 Phase 2 Lenvatinib
30 A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake Completed NCT01413113 Phase 1 pazopanib hydrochloride
31 Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection Recruiting NCT04514484 Phase 1 Cabozantinib S-malate
32 Cognitive Functions and Mood During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma Unknown status NCT02665325 TSH-suppressive therapy
33 Significance of Single Center, Open and Prospective Evaluation of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma. Unknown status NCT03845647
34 Effectiveness of [124I]-PET/CT and [18F]-FDG-PET/CT for Localizing Recurrence in Patients With Differentiated Thyroid Carcinoma Who Have Elevated Serum Thyroglobulin Levels But Are Tumor-negative on Conventional Imaging Studies Unknown status NCT01374659
35 Is the Thyroglobulin Measurement Under Thyroxine of Prognostic Value Before rhTSH-Aided Radioiodine Ablation in Differentiated Thyroid Carcinoma? Completed NCT00439127
36 Clinical Evaluation of a New Highly Sensitive Thyroglobulin Assay in Differentiated Thyroid Carcinoma Completed NCT00148213
37 Post-Marketing Surveillance of Lenvima in Korean Patients Completed NCT02764554
38 A Study to Evaluate and Compare the Surgical Outcomes, Aesthetic Effects and Incision Length of Different Access Procedures in Patients With DTC Completed NCT03239769
39 The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience Completed NCT04500925
40 Relationship Between Estimated Glomerular Filtration Rate and Biological Half-life of 131I. Prospective Analysis in Patients With Differentiated Thyroid Carcinoma. Recruiting NCT02773667
41 Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma- A Multi-Center Validation Study Recruiting NCT05078853
42 Clinical Evaluation of a I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer Using PROBE Design Recruiting NCT01704586
43 Spanish Observational Study for MOLecular Characterization of THYroid Carcinoma MOLTHY Project Recruiting NCT04970134
44 Evaluation of F-18 Tetrafluoroborate (18F-TFB) PET/CT in Patients With Differentiated Thyroid Cancer Recruiting NCT05575440
45 Drug Use Investigation of Sorafenib/ NEXAVAR® for Unresectable Differentiated Thyroid Carcinoma (DTC) Active, not recruiting NCT02185560 Sorafenib (Nexavar, BAY43-9006)
46 Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors -- A Pilot Study Active, not recruiting NCT02592356 Cabozantinib;Lenvatinib
47 Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma Patients Without Metastasis: a Double-blind Randomized Clinical Trial Not yet recruiting NCT04354324 Radioiodine
48 The Uptake of Radioactive Iodine Before and After a Low Iodine Diet in Patients With Differentiated Thyroid Carcinoma Not yet recruiting NCT05599139
49 Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer Not yet recruiting NCT04916262

Search NIH Clinical Center for Differentiated Thyroid Carcinoma

Genetic Tests for Differentiated Thyroid Carcinoma

Genetic tests related to Differentiated Thyroid Carcinoma:

# Genetic test Affiliating Genes
1 Differentiated Thyroid Carcinoma 28

Anatomical Context for Differentiated Thyroid Carcinoma

Organs/tissues related to Differentiated Thyroid Carcinoma:

MalaCards : Thyroid, Lymph Node, Salivary Gland, Endothelial, Bone, Lung, Trachea

Publications for Differentiated Thyroid Carcinoma

Articles related to Differentiated Thyroid Carcinoma:

(show top 50) (show all 3580)
# Title Authors PMID Year
1
Clinical outcomes of a cohort of 271 patients with lung metastases from differentiated thyroid carcinoma. 62
35192239 2022
2
Second Adjuvant Radioiodine Therapy after Reoperation for Locoregionally Persistent or Recurrent Papillary Thyroid Carcinoma. 62
36398303 2022
3
Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review. 62
36060901 2022
4
Preradioactive Iodine Thyroglobulin Levels as Predictors of Metastasis in Well-Differentiated Thyroid Carcinoma Patients. 62
36398311 2022
5
The effect of surveillance for differentiated thyroid carcinoma in childhood cancer survivors on survival rates: a decision-tree-based analysis. 62
36240044 2022
6
2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. 62
36228315 2022
7
Clinical irrelevance of lower titer thyroglobulin autoantibodies in patients with differentiated thyroid carcinoma. 62
36169927 2022
8
The effect of sodium iodide symporter protein on ablation success in patients with differentiated thyroid cancer. 62
36214955 2022
9
Predictors of maximum efficacy of lenvatinib for real-world patients with differentiated thyroid carcinoma. 62
35411497 2022
10
Thyroglobulin antibodies: Trend over time and clinical impact in differentiated thyroid carcinoma with and without radioiodine ablation. 62
36470645 2022
11
Significance of oncocytic features in poorly differentiated thyroid carcinoma - a bi-institutional experience. 62
36346459 2022
12
Clinicopathological features and prognostic factors analysis of multiple synchronous distinct subtypes of primary thyroid carcinoma. 62
36399310 2022
13
Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline. 62
35900783 2022
14
TSH-β gene polymorphism in Saudi patients with thyroid cancer: A case-control study. 62
36465847 2022
15
EIF1AX mutation in thyroid tumors: a retrospective analysis of cytology, histopathology and co-mutation profiles. 62
36371345 2022
16
B3 thymoma mimicking poorly differentiated thyroid carcinoma: Diagnostic pitfalls of anterior mediastinal mass fine needle aspiration. 62
36354028 2022
17
Impact of Lymph Node Dissection on Postoperative Complications of Total Thyroidectomy in Patients with Thyroid Carcinoma. 62
36358878 2022
18
Fluctuations in thyroid hormone levels during initial treatment for differentiated thyroid carcinoma are associated with changes in hemostasis: a prospective cohort study. 62
36322715 2022
19
Rare sites of metastases in patients with differentiated thyroid carcinoma and added value of SPECT/CT over planar whole body radioactive iodine scan. 62
36437402 2022
20
Understanding the effect of obesity on papillary thyroid cancer: is there a need for tailored diagnostic and therapeutic management? 62
36203362 2022
21
The 2022 WHO Classification of thyroid tumors: novel concepts in nomenclature and grading. 62
36445235 2022
22
Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid. 62
36428458 2022
23
PET/CT in nuclear endocrinology: Results of the survey diffused through different social networks of the SEMNIM in Spain. 62
36403726 2022
24
The effect of COVID-19 process on patients with endocrinological disease in a pandemic hospital: What happened to the others? 62
36219200 2022
25
The pathogenesis and treatment differences between differentiated thyroid carcinoma and medullary thyroid carcinoma. 62
35621192 2022
26
Aggressive variants of follicular cell-derived thyroid carcinoma: an overview. 62
35864338 2022
27
Pattern of Nodal Metastasis in Relation to Size of the Primary Tumour in Well-Differentiated Thyroid Carcinoma. 62
36452724 2022
28
Can Serum Thyroglobulin Levels Help to Identify the Involved Neck Compartment of Differentiated Thyroid Carcinoma? 62
36055278 2022
29
Lenvatinib in multimodal therapy for unresectable radioactive iodine-naïve differentiated thyroid cancer: A case report with literature review. 62
35715880 2022
30
Thyroidectomy for the Management of Differentiated Thyroid Carcinoma and their Outcome on Early Postoperative Complications: A 6-year Single-Centre Retrospective Study. 62
36318685 2022
31
Advances in Thyroid Pathology: High Grade Follicular cell-derived Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. 62
36306188 2022
32
Radioiodine Uptake in Incidentally Detected Neuroendocrine Tumor: Correlative Imaging With FDG PET/CT and 68 Ga-DOTATATE PET/CT. 62
35485856 2022
33
Circumferential Laryngotracheal Resection in Thyroid Cancer: Experience and Outcome in a Single Center. 62
36452789 2022
34
Progressive diastolic dysfunction in survivors of pediatric differentiated thyroid carcinoma. 62
35947635 2022
35
Successful dose escalation of lenvatinib for thyroid cancer after disease progression. 62
35737285 2022
36
Adherens Junction Integrity Is a Critical Determinant of Sodium Iodide Symporter Residency at the Plasma Membrane of Thyroid Cells. 62
36358781 2022
37
Retraction Note to: Inhibition of microRNA‑875‑5p promotes radioiodine uptake in poorly differentiated thyroid carcinoma cells by upregulating sodium-iodide symporter. 62
35836040 2022
38
Oncological Outcome Prediction in Differentiated Thyroid Carcinoma: Assumption or Improved Accuracy? 62
35838119 2022
39
Genetic signature of differentiated thyroid carcinoma susceptibility: a machine learning approach. 62
35976137 2022
40
Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive-resistant differentiated thyroid cancer. 62
36202607 2022
41
Active Surveillance for Low-Risk Differentiated Thyroid Cancer. 62
36270610 2022
42
Analysis of Residence Time, Effective Half-Life, and Internal Dosimetry Before Radioiodine Therapy. 62
36215644 2022
43
[A preliminary study on the establishment of trachea respiratory passage invaded by thyroid malignant tumor]. 62
36177560 2022
44
[Surgical management of local advanced differentiated thyroid carcinoma]. 62
36177574 2022
45
Total thyroidectomy with central and lateral neck dissection for poorly differentiated thyroid carcinoma (with video). 62
36192308 2022
46
Microvessel density in differentiated thyroid carcinoma: A systematic review and meta-analysis. 62
36186751 2022
47
A predictive model and survival analysis for local recurrence in differentiated thyroid carcinoma. 62
34528778 2022
48
Letter to the editor regarding "Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival". 62
35704058 2022
49
Multi-center evaluation of the highly sensitive Abbott ARCHITECT and Alinity thyroglobulin chemiluminescent microparticle immunoassay. 62
35837992 2022
50
Vitamin D Status and VDR Polymorphisms as Prognostic Factors in Differentiated Thyroid Carcinoma. 62
36099120 2022

Variations for Differentiated Thyroid Carcinoma

Expression for Differentiated Thyroid Carcinoma

Search GEO for disease gene expression data for Differentiated Thyroid Carcinoma.

Pathways for Differentiated Thyroid Carcinoma

Pathways related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Super pathways Score Top Affiliating Genes
1 13.77 RET PPARG NTRK3 NTRK1 NRAS LPAR4
2
Show member pathways
13.38 ALK BRAF ETV6 HRAS KRAS NRAS
3
Show member pathways
13.27 NTRK3 NTRK1 NRAS KRAS HRAS BRAF
4
Show member pathways
13.08 NTRK3 NTRK1 NRAS KRAS HRAS BRAF
5
Show member pathways
13.06 NTRK3 NTRK1 NRAS KRAS HRAS ALK
6
Show member pathways
12.95 NTRK1 NRAS LPAR4 KRAS HRAS
7
Show member pathways
12.89 BRAF EIF1AX HRAS KRAS NRAS
8
Show member pathways
12.86 NRAS NCOA4 KRAS HRAS BRAF
9
Show member pathways
12.86 NTRK3 NTRK1 NRAS KRAS HRAS BRAF
10
Show member pathways
12.75 PPARG NRAS KRAS HRAS BRAF
11
Show member pathways
12.71 NRAS KRAS HRAS BRAF ALK
12 12.7 ALK BRAF HRAS KRAS NRAS NTRK1
13
Show member pathways
12.68 PPARG NRAS KRAS HRAS BRAF
14
Show member pathways
12.64 NTRK3 NTRK1 NRAS KRAS HRAS
15
Show member pathways
12.5 NRAS KRAS HRAS BRAF
16
Show member pathways
12.48 NTRK3 NTRK1 NRAS KRAS HRAS BRAF
17
Show member pathways
12.46 NTRK3 NTRK1 HRAS BRAF
18
Show member pathways
12.46 NRAS KRAS HRAS BRAF
19
Show member pathways
12.41 NTRK3 NTRK1 NRAS KRAS HRAS
20 12.38 NTRK1 NRAS KRAS HRAS BRAF
21
Show member pathways
12.27 NRAS KRAS HRAS BRAF
22
Show member pathways
12.26 NRAS KRAS HRAS BRAF
23 12.25 HRAS KRAS NRAS NTRK1
24
Show member pathways
12.2 RET NRAS KRAS HRAS
25
Show member pathways
12.15 NRAS KRAS HRAS BRAF
26
Show member pathways
12.15 NTRK3 NTRK1 NRAS KRAS HRAS BRAF
27
Show member pathways
12.13 ETV6 HRAS KRAS NRAS
28
Show member pathways
12.12 NRAS KRAS HRAS BRAF
29
Show member pathways
12.11 NTRK1 NRAS KRAS HRAS BRAF
30
Show member pathways
12.07 NTRK3 NTRK1 NRAS KRAS HRAS BRAF
31
Show member pathways
11.98 PPARG NRAS KRAS HRAS
32 11.97 PPARG KRAS HRAS
33
Show member pathways
11.97 NRAS KRAS HRAS
34 11.97 NRAS KRAS HRAS BRAF
35
Show member pathways
11.94 NRAS KRAS HRAS
36 11.93 NRAS KRAS HRAS
37
Show member pathways
11.91 NRAS KRAS HRAS
38
Show member pathways
11.91 NRAS KRAS HRAS
39 11.89 PPARG KRAS BRAF
40
Show member pathways
11.89 NRAS KRAS HRAS
41
Show member pathways
11.86 NRAS KRAS HRAS
42
Show member pathways
11.84 NRAS KRAS HRAS
43
Show member pathways
11.79 NRAS KRAS HRAS
44
Show member pathways
11.77 NRAS KRAS HRAS
45
Show member pathways
11.76 HRAS KRAS NRAS PPARG
46 11.75 NRAS KRAS HRAS
47 11.64 NTRK3 NTRK1 NRAS KRAS HRAS BRAF
48 11.63 HRAS KRAS NRAS
49
Show member pathways
11.63 HRAS KRAS NRAS
50
Show member pathways
11.63 NRAS KRAS HRAS BRAF

GO Terms for Differentiated Thyroid Carcinoma

Cellular components related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 9.32 RET PPARG NTRK3 NTRK1 ALK

Biological processes related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.22 RET PPARG NTRK3 KRAS HRAS BRAF
2 negative regulation of neuron apoptotic process GO:0043524 10.06 NTRK1 KRAS HRAS BRAF
3 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 10.03 RET NTRK3 NTRK1 ALK
4 positive regulation of protein phosphorylation GO:0001934 10.02 BRAF HRAS KRAS NTRK1 NTRK3
5 positive regulation of kinase activity GO:0033674 9.92 RET NTRK3 NTRK1 ALK
6 cellular response to retinoic acid GO:0071300 9.7 NDUFA13 NTRK3 PPARG RET
7 neurotrophin signaling pathway GO:0038179 9.58 NTRK3 NTRK1
8 multicellular organism development GO:0007275 9.56 RET NTRK3 NTRK1 ALK
9 peptidyl-tyrosine phosphorylation GO:0018108 9.56 RET NTRK3 NTRK1 BRAF ALK
10 MAPK cascade GO:0000165 9.32 RET NRAS KRAS HRAS BRAF

Molecular functions related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.92 RET NTRK3 NTRK1 NRAS KRAS HRAS
2 G protein activity GO:0003925 9.85 NRAS KRAS HRAS
3 GPI-linked ephrin receptor activity GO:0005004 9.71 NTRK3 NTRK1
4 neurotrophin receptor activity GO:0005030 9.56 NTRK1 NTRK3
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.56 RET NTRK3 NTRK1 ALK
6 neurotrophin binding GO:0043121 9.46 NTRK1 NTRK3
7 protein tyrosine kinase activity GO:0004713 9.23 RET NTRK3 NTRK1 BRAF ALK

Sources for Differentiated Thyroid Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....